Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 232Lymphoma 46Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 40Recurrence 30Lymphoma, Non-Hodgkin 29Lymphoma, Follicular 26Leukemia, Myeloid, Acute 25Lymphoma, Large B-Cell, Diffuse 22Waldenstrom Macroglobulinemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell, Marginal Zone 19Leukemia, Lymphocytic, Chronic, B-Cell 19Carcinoma, Non-Small-Cell Lung 18Leukemia 15Hodgkin Disease 13Neoplasms 12Immunoglobulin Light-chain Amyloidosis 12Hematologic Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 9Myelodysplastic Syndromes 9Lymphoma, B-Cell 9Burkitt Lymphoma 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large-Cell, Anaplastic 8Head and Neck Neoplasms 8Congenital Abnormalities 8Breast Neoplasms 8Sarcoma 7Lymphoma, Extranodal NK-T-Cell 7

Interventions

Rocuronium 2ziprasidone 1perflutren 1peginesatide 1hematide 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Thalidomide 1Spironolactone 1Sevelamer 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Molindone 1Methylprednisolone 1Lurasidone Hydrochloride 1Labetalol 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1High-Energy Shock Waves 1Haloperidol 1Fosfomycin 1Dexamethasone 1DM199 1Clozapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Renal Insufficiency, Chronic × Bortezomib × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡